Immunovant, Inc.·4

Dec 20, 4:54 PM ET

MIDDLEKAUFF W BRADFORD 4

4 · Immunovant, Inc. · Filed Dec 20, 2019

Insider Transaction Report

Form 4
Period: 2019-12-18
MIDDLEKAUFF W BRADFORD
General Counsel
Transactions
  • Award

    Stock Option (right to buy)

    2019-12-18+211,277211,277 total
    Exercise: $7.86Exp: 2029-05-19Common Stock (211,277 underlying)
  • Award

    Stock Option (right to buy)

    2019-12-18+489489 total
    Exercise: $7.86Exp: 2029-06-19Common Stock (489 underlying)
Footnotes (3)
  • [F1]25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter.
  • [F2]In connection with the share exchange transaction pursuant to which Health Sciences Acquisitions Corporation ("HSAC") acquired 100% of the issued and outstanding shares of Immunovant Sciences Ltd. (the "Business Combination Transaction"), the option to purchase 432,000 shares of Immunovant Sciences Ltd. at exercise price of $3.84 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer (formerly known as HSAC).
  • [F3]In connection with the Business Combination Transaction, the option to purchase 1,000 shares of Immunovant Sciences Ltd. at exercise price of $3.84 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION